From July 21 to 25, the 2021 mith Conference (full name: China Pharmaceutical and health industry symbiosis Conference) was grandly held in Kunming, and Wanbang xinnuokan, the core product of wanbond Pharmaceutical Group, was held ® After the Ginkgo biloba dropping pill was listed in the "Chinese medicine · brand list" in 2020, it was once again listed as the only Ginkgo biloba preparation variety in the list and the hospital terminal in the "Chinese medicine · brand list" in 2021. This is not only a comprehensive symbol of enterprise strength and influence, but also a prominent manifestation of product competitiveness and brand strength.
On July 21-25, the 2021 Mies Conference (full name: China Pharmaceutical and health industry symbiosis Conference) was grandly held in Kunming. With the theme of "looking for certainty - new ecology, new order and new future", a series of top 100 activities and a series of industry hot spot reports of China's pharmaceutical industry and chain pharmacies were officially released.
On the evening of the 24th, through nearly half a year of data monitoring and online collection, and through the comprehensive evaluation of various expert group committees, the selected "China medicine · brand list" was grandly announced at the conference ® After being listed in the "Chinese medicine · brand list" in 2020, Ginkgo biloba dropping pill was once again listed as the only Ginkgo biloba preparation variety in the "Chinese medicine · brand list" of hospital terminals - drugs for heart and brain diseases (Chinese patent medicines) in 2021. This not only marks Wanbang xinnuokan ® Through unremitting efforts, it has gradually grown into a leading brand in domestic Ginkgo biloba preparation products, which is also the best affirmation of wanbond's efforts to continuously tap more core competitiveness of Ginkgo biloba dropping pills in recent years!
Wanbang xinnuokan ® Ginkgo biloba dropping pills
Wanbang xinnuokan produced by Wanbang Pharmaceutical Group ® Ginkgo biloba dropping pill is a national basic drug variety, national medical insurance variety and national traditional Chinese medicine protection variety. It is an innovative product of traditional oral preparations of modern traditional Chinese medicine. It is a national exclusive dropping pill variety with independent intellectual property rights. It is also a key demonstration research variety of academician and expert team of Ginkgo biloba dropping pill medical research enterprise collaborative innovation alliance, the country's first medical product collaborative innovation alliance.
Wanbang xinnuokan ® Ginkgo biloba dropping pill has the function of promoting blood circulation, removing blood stasis and dredging collaterals. As a first-line drug for the prevention and treatment of cardiovascular and cerebrovascular diseases, it is mainly applicable to the treatment of multiple diseases in Neurology (encephalopathy), cardiovascular medicine, geriatrics and other departments, including stable coronary heart disease, chronic stable angina pectoris, transient ischemic attack, cerebral infarction, sudden deafness Arrhythmia, atherosclerosis, hyperglycemia, hypertension, insomnia and other diseases.
Wanbang xinnuokan ® Ginkgo biloba dropping pills are not only recommended and included by more than 10 clinical guidelines, expert consensus and the interpretation of clinical pathway prepared under the guidance of the National Health Commission, but also widely praised by the society and industry and won many awards. In addition, the authoritative evidence-based medicine - systematic evaluation and meta-analysis results show that Ginkgo biloba dropping pills have good therapeutic effects on the improvement of blood lipid and hemorheology, hypertension and angina pectoris.